Bidirectional synaptic plasticity occurs locally at individual synapses during long-term potentiation (LTP) or long-term depression (LTD), or globally during homeostatic scaling. LTP, LTD, and homeostatic scaling alter synaptic strength through changes in postsynaptic AMPA-type glutamate receptors (AMPARs), suggesting the existence of overlapping molecular mechanisms. Phosphorylation controls AMPAR trafficking during LTP/LTD. We addressed the role of AMPAR phosphorylation during homeostatic scaling. We observed bidirectional changes of the levels of phosphorylated GluA1 S845 during scaling, resulting from a loss of protein kinase A (PKA) from synapses during scaling down and enhanced activity of PKA in synapses during scaling up. Increased phosphorylation of S845 drove scaling up, while a knockin mutation of S845, or knockdown of the scaffold AKAP5, blocked scaling up. Finally, we show that AMPARs scale differentially based on their phosphorylation status at S845. These results show that rearrangement in PKA signaling controls AMPAR phosphorylation and surface targeting during homeostatic plasticity.
INTRODUCTION
In response to different types of stimuli, synapses of the CNS have the ability to change their strength in a bidirectional manner, a phenomenon known as synaptic plasticity. The most wellstudied forms of synaptic plasticity are long-term potentiation (LTP) and long-term depression (LTD), collectively referred to as Hebbian plasticity. LTP and LTD occur at individual synapses, thus altering the strength of affected synapses relative to nearby unaffected synapses (Malenka and Bear, 2004) . It is widely speculated that the changes in relative synaptic strength via Hebbian plasticity form the molecular and cellular basis of learning and memory. Synapses can also undergo a distinct type of plasticity, known as homeostatic scaling, during which many or all synapses on a given neuron simultaneously change in synaptic strength in a uniform direction (O'Brien et al., 1998; Turrigiano et al., 1998) . Unlike Hebbian plasticity, homeostatic scaling alters the strength of all synapses proportionally (Turrigiano et al., 1998) , thus protecting the relative differences in synapse strengths. However, homeostatic plasticity has also been shown to occur at individual synapses (Bé ïque et al., 2011; Lee et al., 2010b) . By engaging homeostatic scaling, neurons are able to adjust their own firing rates toward an ideal set point without disrupting differences in synaptic weights that store information. In this way, homeostatic scaling may function to maintain network stability and promote learning and memory by offsetting the destabilizing effects of continued LTP or LTD (Turrigiano, 2008) . However, at present the relationship between Hebbian and homeostatic plasticity is not clear (Arendt et al., 2013) , and how scaling is able to proceed without disrupting or erasing the information from previous Hebbian plasticity events is unknown. Furthermore, it is unclear how global and local plasticity simultaneously occur to allow network stability and ongoing learning and memory formation. LTP, LTD, and homeostatic scaling each alter synaptic strength in large part by altering the abundance of AMPA-type glutamate receptors (AMPARs) in the postsynaptic membrane (Huganir and Nicoll, 2013; Kessels and Malinow, 2009; Malenka and Bear, 2004; O'Brien et al., 1998; Shepherd and Huganir, 2007; Turrigiano, 2008) . The shared molecular output of these different plasticity types strongly suggests that local and global plasticity cannot occur independently, but rather that the two plasticity types will necessarily have elaborate crosstalk or feedback.
Tetrameric AMPARs are made from the subunits GluA1-GluA4 and mediate the majority of fast excitatory synaptic transmission in the CNS. The majority of AMPARs in the hippocampus and cortex are composed from GluA1/2 and GluA2/3 subunit combinations (Lu et al., 2009; Wenthold et al., 1996) . Phosphorylation of AMPAR cytoplasmic C-terminal tails has been shown to have a prominent role in controlling AMPAR synaptic targeting as well as channel properties (Shepherd and Huganir, 2007) . During the induction and maintenance of LTP and LTD, it has been clearly demonstrated that changes in AMPAR phosphorylation occur and that these phosphorylation sites regulate LTP and LTD (Lee et al., 1998 (Lee et al., , 2003 . In particular, phosphorylation sites, including the PKA-target GluA1 S845 (Roche et al., 1996) , the CaMKII/PKC-target GluA1 S831 (Mammen et al., 1997) , and the PKC-target GluA2 S880 (Chung et al., 2000) , have been well characterized. PKA-mediated phosphorylation of GluA1 S845 has been shown to promote GluA1 cell-surface insertion and synaptic retention, increase channel open probability, and facilitate the induction of LTP (Banke et al., 2000; Ehlers, 2000; Esteban et al., 2003; Lee et al., 2003; Man et al., 2007; Oh et al., 2006) , while dephosphorylation of GluA1 S845 is associated with endocytosis and LTD (Ehlers, 2000; Lee et al., 2000 Lee et al., , 2003 Man et al., 2007) . CaMKII-mediated phosphorylation of GluA1 S831 increases channel conductance and regulates LTP (Derkach et al., 1999; Kristensen et al., 2011; Lee et al., 2000 Lee et al., , 2003 . Finally, PKC-mediated phosphorylation of GluA2 S880 disrupts the interaction between GluA2 and GRIP, allowing for AMPAR endocytosis and LTD (Chung et al., 2000; Seidenman et al., 2003; Steinberg et al., 2006) . Whether changes in AMPAR phosphorylation also occur during homeostatic scaling has not been fully addressed, nor is it clear whether AMPAR phosphorylation is necessary for homeostatic scaling to occur. It is possible that AMPARs may scale differentially depending on the patterns of phosphorylation that occurred during earlier LTP or LTD events. In this way AMPAR phosphorylation may form part of the molecular code to coordinate both global and local synaptic plasticity.
Levels of protein phosphorylation are governed by the opposing activities of protein kinases and phosphatases. Scaffold proteins, such as the A-kinase anchor proteins (AKAPs), can serve as signaling hubs that link second messenger systems, kinases, and phosphatases with particular targets. AKAP5 (also called AKAP79 in humans or AKAP150 in rodents) is a prominent synapse-targeted AKAP that links adenyl cyclase, protein kinase A (PKA), protein kinase C (PKC), and Ca
2+
-dependent protein phosphatase calcineurin/PP2B (CaN) with AMPARs (Colledge et al., 2000; Sanderson and Dell'Acqua, 2011; Tavalin et al., 2002 ). In the current study, we show that changes in the coupling of AMPARs with PKA occur via the scaffold AKAP5. Reduction in AMPAR-PKA coupling during scaling down results in a decrease in the level of phosphorylated AMPARs and a reduced ability to phosphorylate AMPARs upon neuromodulator stimulation. During scaling up, overall PKA activity is low, but (A) Cortical neurons (13 DIV) were treated 24 or 48 hr with control media (Con), bicuculline (Bic, 20 mM), or tetrodotoxin (TTX, 1 mM), followed by surface biotinylation and western blot.
(B) Quantification of cell-surface levels of the AMPAR subunits GluA1, GluA2, or GluA3.
(C) Quantification of total levels of phosphorylated GluA1 S845 or S831 or GluA2 S880. Values relative to control, indicated by the dashed line. *p < 0.05, **p < 0.01. Error bars indicate ± SEM. n = 4-6 independent experiments. See also Figure S1 .
active PKA is concentrated into dendritic spines, resulting in AMPAR S845 phosphorylation and an increased ability to phosphorylate AMPARs upon neuromodulator stimulation. This reorganization of PKA signaling requires the scaffold AKAP5. A GluA1 S845A knockin mutation that eliminated phosphorylation, abolished scaling up, while enhancement of S845 phosphorylation can drive scaling up. Further, we find that phospho-S845 receptors are resistant to scaling down, showing that AMPARs scale differentially based on their phosphorylation status. Finally, using a glycine-based chemical LTP protocol, we show that rearrangements of the PKA signaling pathway following homeostatic scaling alter the ability of cortical neurons to express LTP. Thus, we demonstrate that, like Hebbian plasticity, homeostatic scaling involves changes in AMPAR phosphorylation, but utilizes distinct mechanisms, and thus interacts with Hebbian synaptic plasticity.
RESULTS

Changes in AMPAR Phosphorylation during Homeostatic Scaling
We first examined AMPAR phosphorylation during homeostatic scaling. Cultured rat cortical neurons were treated with bicuculline or tetrodotoxin (TTX) for 24 or 48 hr, treatments previously shown to induce homeostatic scaling down and scaling up, respectively (O'Brien et al., 1998; Turrigiano et al., 1998) . To monitor the progress of scaling, neurons were surface biotinylated, and surface AMPARs were detected by western blot. Bicuculline treatment resulted in a loss of surface GluA1, GluA2, and GluA3 after 48 hr and (to a lesser degree) after 24 hr. TTX treatment resulted in increased surface GluA1 and GluA2 only after 48 hr of treatment ( Figures 1A and 1B) . Thus, bidirectional homeostatic scaling is clearly induced after 48 hr in our system. Interestingly, TTX treatment did not result in an increase in surface GluA3, even after 48 hr, showing that scaling up likely involves GluA1/2 and not GluA2/3 receptor subunit combinations ( Figures 1A and 1B) . Using phosphospecific antibodies, we examined the levels of phospho-S831 and phospho-S845 on GluA1 and phospho-S880 on GluA2, well-characterized sites previously shown to be involved in Hebbian plasticity (Shepherd and Huganir, 2007) . Bicuculline treatment for 48 hr resulted in a significant decrease in AMPA receptor phosphorylation at all (legend continued on next page) three sites ( Figures 1A and 1C) , with the phospho-S845 levels showing the most prominent decrease. TTX treatment for 48 hr resulted in a significant increase in phospho-S845 levels, but not phospho-S831 or phospho-S880 levels ( Figures 1A and  1C ). This pattern of S845 phosphorylation was not observed following acute (10 min) bicuculline or TTX treatment (Figures S1A and S1B, available online). Therefore, changes in AMPAR phosphorylation occur during homeostatic scaling.
Reorganization of PKA Signaling during Homeostatic Scaling As the PKA-target GluA1 S845 showed the most prominent changes in phosphorylation during homeostatic scaling, we next addressed the molecular basis for changes in AMPAR phosphorylation by PKA. Following a 48 hr treatment with bicuculline or TTX, we first examined protein levels of PKA, calcineurin (CaN), AKAP5, and the b2-adrenergic receptor, as these proteins are all known to regulate synapse targeting of GluA1 and phosphorylation of S845 (Hu et al., 2007; Joiner et al., 2010; Jurado et al., 2010; Zhang et al., 2013) . We observed no change in the levels of the PKA catalytic subunit or the b2-adrenergic receptor following scaling. After bicuculline treatment to induce scaling down, there were small but significant decreases in the levels of the catalytic subunit of CaN and AKAP5 ( Figures  2A and 2B ). Decreased CaN phosphatase upon bicuculline treatment would be expected to result in increased GluA1 S845 phosphorylation, contrary to our observations. On the other hand, AKAP5 is known to anchor PKA with the GluA1 AMPAR subunit (Sanderson and Dell'Acqua, 2011) . Therefore, the decrease in AKAP5 protein following bicuculline treatment suggested that a loss of coupling between PKA and GluA1 may be responsible for decreased S845 phosphorylation during scaling down.
To address this possibility, we treated neurons with bicuculline or TTX for 48 hr to induce scaling and then challenged the neurons for 5 min with isoproterenol (10 nM), a noradrenaline analog known to cause cyclic AMP (cAMP)/PKA-mediated phosphorylation of GluA1 S845 through the b2-adrenergic receptor (Hu et al., 2007; Joiner et al., 2010) . As expected, isoproterenol challenge resulted in a clear increase in phospho-S845 levels in previously untreated neurons. Interestingly, phosphorylation of S845 following isoproterenol challenge was significantly reduced in neurons pretreated with bicuculline and increased in neurons pretreated with TTX ( Figures 2C and 2D ). As the protein levels of the b2-adrenergic receptor were not altered, we believe these observations are the result of suppression or enhancement of PKA activity toward GluA1 during scaling down or up, respectively. Indeed, this phosphorylation pattern was not observed at nonsynaptic PKA targets, such as CREB (S133) or inhibitor protein 1 (I-1, T35), upon isoproterenol treatment ( Figures S1C and S1D ) or at the PKC target GluA2 S880 upon PKC activation with phorbol ester PMA (Figures S1E and S1F). In addition, acute treatment with bicuculline or TTX did not affect isoproterenol-induced phosphorylation of S845 (Figures S1A and S1B) . Therefore, not only are the levels of phosphorylated GluA1 S845 altered during homeostatic scaling, but the ability of PKA to phosphorylate GluA1 in response to stimuli is altered. These results suggest the specific rearrangements of PKA signaling at the synapse during scaling.
We also examined the cellular distribution and association of PKA and AKAP5 during homeostatic scaling using immunofluorescence microscopy and coimmunoprecipitation (coIP), respectively. The PKA catalytic subunit showed prominent dendritic shaft targeting (Zhong et al., 2009 ) but nonetheless could also be detected in dendritic spines, shown using a GFP cell fill or overlap with the synapse marker PSD95. We determined a spine enrichment value by measuring the staining intensity of PKA in the dendritic spines versus the dendritic shaft. We observed a significant decrease in the localization of PKA to dendritic spines following 48 hr bicuculline treatment but no change following TTX treatment (Figures 2E and 2F) . AKAP5 was more enriched in dendritic spines, and this distribution was not altered during homeostatic scaling (Figures 2G and 2H) . The removal of PKA, but not AKAP5, from dendritic spines during scaling down suggests that the association between the two proteins may be decreased. Indeed, we detected a decrease in the coimmunoprecipitation of PKA and AKAP5 following bicuculline treatment ( Figure 2I ).
In parallel, we were also interested in the overall level and distribution of PKA activity during homeostatic scaling. To address this, we performed western blot on control, bicuculline-, or TTXtreated samples using an antibody raised against a consensus PKA phosphosubstrate. We found that the overall western blot signal was not altered in bicuculline-treated samples compared to untreated samples but was significantly reduced in TTXtreated samples (Figures 3A and 3B) . No significant changes were seen under these conditions using a similar PKC phosphosubstrate antibody (Figures 3A and 3B) . We confirmed that these antibodies were phosphospecific ( Figure S2 ). Next, we examined the dendritic distribution of PKA activity during homeostatic scaling using a previously developed fluorescence-resonance energy transfer (FRET) sensor, A-kinase activity reporter (AKAR4) (Depry et al., 2011; Zhang and Allen, 2007) . This reporter contains a PKA target site and upon phosphorylation undergoes a conformational shift resulting in an increased FRET signal. Using this FRET reporter, we found PKA activity distributed equally in dendritic spines and dendritic shaft in control neurons. Following bicuculline treatment, there was a significant reduction in PKA activity in dendritic spines relative to dendritic shaft. In contrast, following TTX treatment, the activity of PKA in dendritic spines was greatly increased compared to that in dendritic shafts ( Figures 3C and 3D ). Finally, we purified postsynaptic densities (PSD) from bicuculline-or TTX-treated neurons ( Figure 3E ) and examined PKA activity in the PSD using the PKA substrate antibody. Unlike the pattern observed in (E-H) Hippocampal neurons (14 DIV) transfected with GFP and treated with bicuculline or TTX. The localization of PKA catalytic subunit (E) or AKAP5 (G) to dendritic spines was observed and quantified (F and H) (n = 50-75 spines each from 11-17 neurons. Scale bar, 5 mm. PKA has strong dendritic shaft localization but is observed in dendritic spines. Following bicuculline treatment, PKA moves out of spines. (I) AKAP5 was immunoprecipitated from bicuculline/TTX-treated cortical neurons (13-14 DIV). Coimmunoprecipitation of PKA is reduced following bicuculline treatment (n = 3). *p < 0.05, **p < 0.01. Error bars indicate ± SEM. See also Figures S1 and S3.
whole-cell lysate, PKA activity in the PSD was increased following TTX treatment (Figures 3F and 3G) . Furthermore, we observed that the scaffold AKAP5 showed a significant increase in PSD association following TTX treatment ( Figures 3F and 3H ). As AKAP5 targeting to dendritic spines is not altered during scaling (Figures 2G and 2H) , it is likely that increased AKAP5 in the PSD is supplied from a perisynaptic pool of AKAP5 molecules. Overall, these findings show that PKA activity is high during scaling down, but there is a loss of PKA protein and activity from dendritic spines and a decrease in PKA phosphorylation of GluA1. During scaling up, overall PKA activity is low, but active PKA is enriched in dendritic spines, allowing increased phosphorylation of GluA1 S845 (summarized in Figure S3 ). These findings further strengthen our hypothesis that PKA signaling, and the access of PKA to its substrate GluA1, is altered during homeostatic scaling and also explain why isoproterenol-induced AMPAR phosphorylation was altered following scaling.
AKAP5 Is Required for Homeostatic Scaling up
Our results point toward a prominent role for AKAP5 in shaping signaling events toward AMPARs during homeostatic scaling. To directly address the role of AKAP5, we transfected neurons with a vector control or with an shRNA against rat AKAP5 (shAKAP5) that effectively reduces its expression ( Figure S4A ). In vector-transfected neurons treated with bicuculline/TTX, we observed the same changes in surface AMPAR subunits and phosphorylation observed in nontransfected cells in Figure 1 ( Figures 4A-4C ). Neurons transfected with shAKAP5 showed reduced levels of AKAP5 protein, but not of the PKA catalytic subunit. In addition, AKAP5 knockdown caused a significant reduction in surface levels of all AMPAR subunits and reduced phosphorylation at GluA1 S845 and S831 and GluA2 S880. This is consistent with the ability of AKAP5 to anchor both PKA and PKC (Sanderson and Dell'Acqua, 2011) . Further decreases in AMPAR phosphorylation and surface levels were still observed in shAKAP5-transfected neurons following bicuculline treatment, suggesting that knockdown of AKAP5 partly mimics scaling down. However, increased GluA1 phospho-S845 and surface GluA1 and GluA2 normally observed upon TTX treatment were completely blocked in AKAP5 knockdown neurons ( Figures  4A-4C ). Surface GluA1 antibody labeling and fluorescence microscopy confirmed that AKAP5 knockdown blocked scaling up and partly mimicked scaling down ( Figures 4D and 4E ). Basal levels of surface GluA1 and bidirectional scaling were restored Global PKA or PKC activity was assessed by western blot of whole-cell lysates using pan phosphosubstrate antibodies.
(B) Quantification of pan phosphosubstrate blots indicates a significant reduction in PKA activity in whole-cell lysate after TTX treatment (n = 6). (C) PKA activity was visualized using a FRET-based A-kinase activity reporter, AKAR4, transfected into cortical neurons (13-15 DIV) treated with bicuculline/ TTX for 48 hr. The false color scale is indicated. Scale bar, 5 mm. by cotransfection with shRNA-resistant human AKAP5 ( Figures  4D and 4E) . Together, these results show that AKAP5 is required for TTX-induced scaling up and that loss of AKAP5 partially occluded bicuculline-induced scaling down. Further, we found that, like bicuculline-induced scaling down, AKAP5 knockdown impaired PKA phosphorylation of GluA1 S845 following isoproterenol treatment ( Figures S4B and S4C) , consistent with previous results (Zhang et al., 2013) .
GluA1 Phospho-S845 Is Required for Scaling up Next, we performed scaling treatments followed by cellsurface biotinylation and western blot, mini-EPSC recording, or immunofluorescence microscopy using wild-type or phosphodeficient transgenic knockin mice in which key serine residues of GluA1 are mutated to alanine (S831A or S845A) (Lee et al., 2010a) . In cultured cortical neurons from wild-type mice treated with bicuculline or TTX, we observed a bidirectional change in surface GluA1 and GluA2, as well as phospho-S845 and decreased surface GluA3 and phospho-S831 and phospho-S880 in response to bicuculline ( Figures 5A and 5B ), similar to rat neurons (Figure 1 ). Bidirectional scaling of surface GluA1 and GluA2 was normal in S831A mutant neurons, but TTXinduced scaling up was completely eliminated in the S845A mutant neurons (Figures 5A and 5B ). Bicuculline-induced scaling down of surface GluA3 was not different between genotypes ( Figures 5A and 5B) . Bicuculline or TTX treatment resulted in changes in total AMPAR expression, in agreement with previous findings (Anggono et al., 2011) , but these alterations in total AM-PAR expression were not affected by mutation of S831 or S845 ( Figure S5A ). Using mEPSC recording, we observed a bidirectional change in mini amplitude in response to bicuculline or TTX in wild-type neurons. TTX treatment resulted in a significant increase in mini amplitude in S831A neurons, while in the S845A neurons the TTX increase in mini amplitude was eliminated (Figures 5C and 5D ). Both S831A and S845A neurons showed a clear trend toward decreased mini amplitude in response to bicuculline, but this was not statistically significant (Figures 5C and 5D) . No changes were seen in mEPSC frequency or decay kinetics ( Figures S5B and S5C ). Using surface GluA1 immunostaining, we observed bidirectional changes in surface GluA1 in WT and S831A neurons in response to bicuculline or TTX treatment, while scaling up was completely blocked in S845A neurons ( Figures 5E and 5F ). Thus, the S845 phosphorylation site of GluA1 is required for homeostatic scaling up. There were no changes in the total or surface levels of GluA1, GluA2, or GluA3 between wild-type, S831A, and S845A neurons in the absence of scaling induction ( Figures S5D and S5E) . Further, mutation of S831 or S845 did not affect the basal phosphorylation levels of the other sites ( Figures S5D and S5E ).
Increasing Phospho-S845 Promotes GluA1 Surface Targeting and Scaling up In order to test how manipulations of phospho-S845 would affect scaling, neurons were treated with bicuculline/TTX in combination with forskolin/rolipram (FR; 2.5 mM/100 nM, 48 hr) to activate PKA or FK506 (2.5 mM, 48 hr) to inhibit CaN, manipulations expected to increase the levels of phospho-S845. FR treatment increased the phosphorylation of GluA1 S845 as expected for this PKA target ( Figures 6A and 6B) . Moreover, FK506 treatment significantly increased the levels of GluA1 phospho-S845, confirming that CaN is a phosphatase that controls basal levels of phospho-S845 (Colledge et al., 2000; Tavalin et al., 2002) (Figures 6A and 6B) . Interestingly, under these conditions we found that FR or FK506 treatment alone resulted in increased surface targeting of GluA1 that completely occluded the effect of TTX ( Figures 6A and 6B ). Bicuculline-induced scaling down in the presence of FR or FK506 seemed to be reduced compared to bicuculline-only treatment, but it was still clearly occurring ( Figures  6A and 6B) . Again, we observed that bicuculline treatment alone caused a loss of phosphorylation at S845. However, when combined with bicuculline, FR treatment prevented the loss of phospho-S845 and maintained this phosphorylation at a high level. Interestingly, during bicuculline treatment, FK506 did not prevent the loss of phosphorylation at GluA1 S845, suggesting that the loss of phospho-S845 is not due to activation of CaN, but likely from a reduction in PKA activity toward GluA1 ( Figures 6A and  6B ). Treatment of wild-type mouse neurons with FR resulted in increased GluA1 surface targeting, but this was not observed in phospho-deficient GluA1 S845A mouse neurons, indicating that FR's effect on GluA1 surface expression was mediated by S845 phosphorylation (Figures S5F and S5G ). Thus, treatments leading to phosphorylation of GluA1 S845, either kinase activation or phosphatase inhibition, promote GluA1 surface targeting. In order to further characterize the effects of PKA activation during scaling, surface GluA1 was labeled in neurons treated with bicuculline, TTX, or FR. We again observed that the increase in surface GluA1 induced by TTX was occluded by FR treatment, but bicuculline-induced scaling down could still occur ( Figures  S6A and S6B) . However, when we costained surface GluA1 with the excitatory synapse marker VGlut1, we observed that FR and TTX treatment had an additive effect in recruitment of surface GluA1 to synaptic sites ( Figures 6C and 6D ). Using electrophysiological recordings, we found that treating neurons with FR or TTX increased mEPSC amplitude similarly, compared to untreated neurons ( Figures 6E and 6F ). When FR was combined with TTX, we observed a further enhancement of mEPSC amplitude ( Figures 6E and 6F) , consistent with enhanced synaptic recruitment of surface GluA1. This finding is in agreement with earlier studies suggesting that PKA activity primarily acts to increase AMPAR surface targeting and that additional signaling can recruit these receptors into the postsynaptic density (Esteban et al., 2003; Oh et al., 2006) . Treatment of FR in combination with bicuculline reduced mEPSC amplitude compared to FR treatment alone ( Figures 6E and 6F) . No changes in mEPSC frequency or decay kinetics were observed ( Figures S6C and S6D) . Together, these results indicate that elevated PKA activity can promote synaptic strengthening and scaling up but that scaling down can still occur.
Phospho-S845 GluA1 Is Resistant to Scaling down
In the previous experiments, we found that under conditions of high PKA activity, the loss of phospho-S845 during scaling down was prevented, but a reduction in surface GluA1 still occurred. This suggests that under certain signaling conditions phospho-S845 AMPARs may be resistant to scaling down and that nonphosphorylated receptors may be preferentially removed. To further test this possibility, we examined the surface and cellular distribution of GluA1 phospho-S845 during homeostatic scaling. Bicuculline-, TTX-, and FR-treated neurons were biotinylated, and surface GluA1 was visualized by western blot. Blots were then stripped and reprobed with the anti-phospho-S845 antibody. Following FR and bicuculline treatment, there was no decrease in phospho-S845 receptors on the cell surface even while a reduction in overall surface GluA1 was observed ( Figures 7A and 7B ), suggesting that phospho-S845 receptors were preferentially retained on the cell surface while nonphosphorylated receptors were removed. As an alternate strategy, we prepared PSD samples from bicuculline-, TTX-, and FR-treated neurons and examined the PSD levels of phos-(C) Following drug treatments, surface GluA1 (magenta) was labeled followed by total VGlut1 (green). Scale bar, 5 mm.
(D) Surface GluA1 fluorescence intensity was quantified only at areas that overlapped with the synapse marker VGlut1 (n = 24 fields). FR treatment increased synaptic surface GluA1 to a degree similar to that of TTX. FR and TTX showed an additive effect. pho-S845 receptors. Again, we observed that FR treatment greatly increased the level of phospho-S845 in the PSD and that this level was maintained in the presence of bicuculline even though GluA1 levels in the PSD were reduced (Figures 7C and 7D) .
Next, we examined the cellular distribution of phospho-S845 receptors. Phospho-S845 receptors could be visualized as punctate structures only when phosphorylation was increased by FR treatment in wild-type, but not in S845A mutant neurons ( Figure S7 ). When we compared the distribution of phospho-S845 punctae in FR-treated neurons to the excitatory synapse marker VGlut1, we saw a very clear overlap, suggesting that phospho-S845 receptors are localized at synapses ( Figure 7E ). When neurons were also treated with bicuculline or TTX, we again observed that the phospho-S845 punctae were synaptic ( Figure 7E ). Together, these results show that under conditions of high-PKA activity, scaling down of GluA1-containing AMPARs can still occur, but phosphorylated receptors remain on the cell surface and at synapses. Thus, AMPARs scale differentially based on their phosphorylation status. 
(legend continued on next page)
Homeostatic Scaling and LTP Finally, we tested how the rearrangements in PKA signaling during scaling influenced LTP. Cortical neurons were first treated with bicuculline or TTX to induce homeostatic scaling and then treated with a glycine-based media that has been well established to induce a form of chemical LTP (cLTP) (Liao et al., 2001; Lu et al., 2001) . Using cell-surface biotinylation and western blot, we observed that glycine treatment in control cells resulted in a significant increase in surface GluA1 as well as phosphorylation of S845. Increases in surface GluA1 and phospho-S845 were completely blocked in neurons pretreated with bicuculline or occluded in neurons pretreated with TTX ( Figures  8A and 8B ). This result was confirmed using cell-surface immunolabeling and fluorescence microscopy ( Figures 8C and 8D ). However, we considered that while scaling blocked/occluded the increase in surface GluA1 by cLTP, preexisting surface receptors could still become enriched at synapses. To test this possibility, we isolated PSD samples from scaled/cLTP-treated neurons and examined the synaptic levels of AMPAR subunits by western blot. In control neurons, cLTP resulted in a clear increase in PSD-associated GluA1 and GluA2, but not NMDAR subunit GluN2B (Figures 8E and 8F) . Synaptic GluA3 showed a trend to increase upon cLTP that was not statistically significant. Interestingly, we saw no change in synaptic AMPAR subunits upon cLTP in neurons pretreated with bicuculline or TTX ( Figures  8E and 8F) . As an alternate strategy, we immunolabeled surface GluA1 followed by staining of the excitatory synapse marker VGlut1. We then examined surface GluA1 levels only at regions positive for VGlut1, and we again conclude that there was an increase in synaptic GluA1 in control but not in scaled neurons ( Figures 8G and 8H ).
Similarly to bicuculline-induced scaling down, knockdown of AKAP5 also blocked the effect of glycine on surface GluA1 (E) Following scaling and cLTP treatments, cortical neurons were fractionated to obtain PSD samples. PSD material was analyzed by western blot. (F) cLTP results in increased levels of synaptic GluA1 and GluA2 in control neurons but not in neurons pretreated with bicuculline or TTX. For each scaling condition, data are presented as glycine treated relative to untreated, indicated by the dashed line (n = 3). (G) Surface GluA1 (magenta) and total VGlut1 (green) were labeled following scaling and cLTP. Scale bar, 5 mm. (H) Surface GluA1 fluorescence intensity was quantified only at areas that overlapped with the synapse marker VGlut1. For each scaling condition, data are presented as glycine treated relative to untreated (n = 35 fields). *p < 0.05, **p < 0.01. ns, no statistical significance. Error bars indicate ± SEM. Scaling involves a change in the coupling of basal PKA with AMPA receptors via AKAP5, resulting in increased or decreased AMPA receptor phosphorylation. LTP and LTD involve the activation and recruitment of kinases or phosphatases, respectively, to increase or decrease AMPA receptor phosphorylation, respectively. Note that AKAP5 also participates in LTP and LTD.
and phospho-S845 (Figures S8A-S8D) . Importantly, expression of human AKAP5 could rescue glycine-induced increases in surface GluA1 in AKAP5 knockdown neurons ( Figures S8C and S8D) . These findings again demonstrate the importance of GluA1-PKA coupling via AKAP5 in controlling AMPA receptor phosphoryllation and surface targeting. Further, these results show that rearrangements of the PKA signaling pathway during homeostatic scaling have important impacts on the ability of cortical neurons to express LTP.
DISCUSSION
Changes in PKA Signaling during Homeostatic Scaling
Previous studies have shown that changes in phosphorylation play a key role in controlling AMPAR synaptic targeting during Hebbian forms of synaptic plasticity (Hu et al., 2007; Lee et al., 2000 Lee et al., , 2003 Seol et al., 2007; Steinberg et al., 2006) . In the current study, we investigated the role of AMPAR phosphorylation in homeostatic scaling, a form of global synaptic plasticity. We were also interested in the possibility that AMPAR phosphorylation may mediate interactions between local (Hebbian) and global (homeostatic) plasticity. AMPAR phosphorylation is governed by the opposing activities of kinases and phosphatases. The activities of these enzymes toward specific substrates are coordinated by scaffold proteins, such as AKAP5 in the case of AMPARs (Sanderson and Dell'Acqua, 2011) . Focusing on three well-characterized phosphorylation sites, we have shown that indeed the level of phosphorylated AMPARs does change during homeostatic scaling. In particular, the level of GluA1 phosphorylated at S845 showed bidirectional changes during homeostatic scaling, and these changes are brought about through changes in the coupling of PKA and GluA1 via the signaling scaffold AKAP5 (Figure 9 ).
During scaling down, PKA becomes uncoupled from the scaffold protein AKAP5 and exits dendritic spines. Even though general PKA activity remains high, this reorganization results in a reduced ability of PKA to access its substrate GluA1, leading to a loss of GluA1 S845 phosphorylation, reduced effectiveness of noradrenaline, and a block of cLTP. During scaling up, general PKA activity is low, but remaining active PKA is enriched in dendritic spines, where it can promote the phosphorylation of GluA1 S845. This rearrangement results in enhanced effectiveness of noradrenaline and an occlusion of cLTP. Both AKAP5 and GluA1 S845 are required for scaling up, and scaling down can be partially occluded by knocking down AKAP5. A recent study found that dark-induced scaling up in the visual cortex also required GluA1 S845 (Goel et al., 2011) . Interestingly, both WT and S845A knockin neurons showed increased expression of GluA1 after TTX treatment, and yet S845A neurons completely lacked scaling up of surface or synaptic AMPARs. This finding suggests that an increase in GluA1 expression levels is not sufficient to promote scaling without phosphorylation of S845. The observed changes in GluA1 phospho-S845 during scaling are consistent with earlier literature showing that phosphorylation of GluA1 S845 promotes surface targeting and LTP and that dephosphorylation promotes GluA1 endocytosis and LTD (Ehlers, 2000; Esteban et al., 2003; Lee et al., 2003; Man et al., 2007; Oh et al., 2006) .
AMPAR Phosphorylation and Global Synaptic Plasticity
One of the defining features of homeostatic scaling is its multiplicative nature, the observation that all synapses on a given neuron seem to be affected to an equal degree. However, the mechanism for multiplicative scaling remains largely unknown. A prevailing model of the excitatory synapse postulates that the PSD contains slots, which can be occupied by trafficking AMPARs (Huganir and Nicoll, 2013; Kessels and Malinow, 2009) . Synaptic AMPARs undergo continuous turnover as receptors exit the PSD, leaving empty slots behind, and are replaced from pools of surface extrasynaptic receptors. A recent study demonstrated that an increased off rate of PSD-anchored AMPARs was one key mechanism contributing to synaptic weakening during homeostatic scaling down (Tatavarty et al., 2013) . This report demonstrated that increased AMPAR off rates would allow for uniform adjustments to synaptic strength, enabling multiplicative scaling down (Tatavarty et al., 2013; Turrigiano, 2008) . However, scaling up appeared to utilize a different mechanism (Tatavarty et al., 2013) . Dephosphorylation of GluA1 S845 is believed to destabilize AMPARs on the cell surface and at the synapse (Ehlers, 2000; Lee et al., 2000 Lee et al., , 2003 Man et al., 2007) . Uncoupling of AMPARs from PKA favors dephosphorylation and may form the molecular basis of this observed destabilization of synaptic AMPARs during scaling down. Conversely, enhanced coupling between PKA and GluA1 via AKAP5 during scaling up may increase the surface pool of receptors that could occupy slots in the PSD, and perhaps increase the slot occupancy in a global fashion, enabling multiplicative scaling up.
LTP has a strong destabilizing effect on neuronal networks due to its feedforward nature, and this is speculated to be offset by scaling down (Turrigiano, 2008) . Another predicted function of scaling down, yet untested, is to increase synaptic signal-tonoise ratios (Turrigiano, 2008) . In this scenario, naive synapses would be more affected than previously potentiated synapses. Either smaller naive synapses could be weakened below a functional threshold or previously potentiated synapses could be resistant, or even escape scaling down altogether. We have shown that when PKA is highly active there is an increase in phosphorylated S845 receptors; during scaling down, these phosphorylated receptors remain on the cell surface, at the synapse, and within the PSD, despite the overall loss of AMPARs from these locations. These results indicate that nonphosphorylated receptors are preferentially removed and that PKA-phosphorylated receptors are resistant to scaling down. It is possible that potentiated synapses may maintain a pool of active kinases and a larger pool of resistant phosphorylated AMPARs, consistent with synaptic tagging (Huang et al., 2006; Sajikumar et al., 2007) . Neuromodulators, such as noradrenaline, that regulate the cAMP/PKA pathway and modulate AMPAR trafficking may also influence scaling (Hu et al., 2007; Joiner et al., 2010; Seol et al., 2007) . During global scaling down, localized innervation of neuromodulators could protect certain synapses from scaling. Therefore, global decreases in kinase-AMPAR coupling, combined with localized PKA signaling during/following LTP or neuromodulator release, offer a mechanistic insight into how scaling down may proceed in a manner sensitive to the previous history of the synapse and achieve an enhanced signal-to-noise ratio in neural networks.
Homeostatic Scaling versus LTP/LTD
During LTP, kinases such as PKA and CaMKII are activated/recruited to phosphorylate AMPARs, promoting receptor insertion and synaptic potentiation (Huganir and Nicoll, 2013; Lee et al., 2000; Malenka and Bear, 2004) . Blocking protein kinases or removing the AMPAR phosphorylation sites can impair LTP (Lee et al., , 2003 Malenka and Bear, 2004) . LTD involves the activation or recruitment of phosphatases such as PP1, PP2A, and CaN, which can dephosphorylate AMPARs, promoting their removal from the synapse (Figure 9 ) (Huganir and Nicoll, 2013; Lee et al., 1998 Lee et al., , 2000 Malenka and Bear, 2004 ). In our model, there is no overt activation or deactivation of kinases or phosphatases during scaling, but rather changes in the ability of basal activities of these enzymes to access AMPARs through changes in coupling via AKAP5 (Figure 9 ). Indeed, overall PKA activity was even suppressed during scaling up. Furthermore, inhibition of CaN with FK506 resulted in increased GluA1 S845 phosphorylation, showing that there is basal PKA activity acting on this site and that this basal PKA activity is balanced by CaN phosphatase activity. During LTD, AMPAR dephosphorylation and synaptic depression can be blocked by FK506 . Loss of AMPAR phosphorylation during scaling down, however, was not prevented by FK506, suggesting that CaN phosphatase is not activated during scaling down. Therefore, our results show that changes in AMPAR phosphorylation occur during scaling and Hebbian plasticity. However, homeostatic scaling employs a fundamentally distinct mechanism (Figure 9 ).
While homeostatic scaling and Hebbian plasticity have important differences in their molecular mechanisms, these plasticity types share substantial overlap as well. An important step in the field will be to understand the relationship between local and global plasticity types. We found that cLTP was occluded by scaling up or blocked by scaling down, suggesting that adjustments to synaptic weights during homeostatic scaling may come at the cost of the neuron's capacity for LTP. Loss of PKA from the synapse during scaling down may explain the block of LTP. Indeed, knockdown or knockout of AKAP5, which anchors PKA in the synapse (Tunquist et al., 2008; Weisenhaus et al., 2010; Zhang et al., 2013) , also blocks LTP, mimicking the effects of scaling down. It has been speculated that scaling down may prevent the feedforward effects inherent in LTP (Turrigiano, 2008) . Therefore, it makes physiological sense that LTP induction (but not maintenance) should be inhibited during scaling down. The occlusion of LTP by scaling up may be explained by a ceiling effect. Increased GluA1 surface targeting and S845 phosphorylation during scaling up cannot be further enhanced by cLTP.
A recent study has shown that LTP is enhanced in relatively young hippocampal slices previously treated with TTX to induce scaling up (Arendt et al., 2013) . The authors observed that scaling up with TTX treatment induced the formation of silent synapses and that LTP induction unsilenced these synapses, resulting in substantial potentiation (Arendt et al., 2013) . Whether active (AMPAR-containing) synapses also underwent potentiation or were already at a ceiling of synaptic strength was not clear. Whether LTP is also enhanced or in fact occluded in older hippocampal slices following scaling up will need to be tested (Soares et al., 2013) . Another possibility is that the relationship between local and global plasticity may be unique in different brain regions or developmental stages, dictated by the physiological function of specific neuron types. Homeostatic plasticity has also been demonstrated at single synapses (Bé ïque et al., 2011; Lee et al., 2010b) . The interaction between single synapse homeostatic plasticity and Hebbian plasticity also requires further investigation.
In conclusion, we have shown that homeostatic scaling involves significant alterations in the PKA signaling pathway, with important consequences on AMPAR phosphorylation and synaptic strength. Further, AMPARs scale differentially based on their phosphorylation status, which may form the basis of interactions between local and global plasticity types.
EXPERIMENTAL PROCEDURES Animal Care
All animals were treated in accordance with the Johns Hopkins University Animal Care and Use Committee Guidelines.
Chemical LTP and Drug Treatment
To induce homeostatic scaling, neurons were treated (unless otherwise stated) for 48 hr with bicuculline methobromide (20 mM) or tetrodotoxin (TTX, 1 mM). For some experiments, these treatments were used in combination with forskolin/rolipram (2.5 mM/100 nM) or FK506 (2.5 mM). For some experiments, neurons were treated with isoproterenol (10 nM) or phorbol-myristoyl-acetate (PMA, 10 nM) for 5 min at the end of the 48 hr scaling treatments or following a 5 min pretreatment with bicuculline or TTX. For chemical LTP experiments, neurons were first preincubated for 15 min at 37 C in chemLTP buffer (125 mM NaCl, 2.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 33 mM glucose, 25 mM HEPES [pH 7.4], 20 mM bicuculline, 500 nM TTX, 1 mM strychnine), followed by glycine treatment for 5 min (chemLTP buffer, 200 mM glycine, 0 magnesium), and then returned to the original buffer (without glycine) for 20 min prior to lysis/fixation. Neurons were used at 13-15 days in vitro (DIV) for all experiments.
Surface Biotinylation
Neurons were rinsed with ice-cold PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 (pH 8.0) (PBSCM), incubated in PBSCM containing 0.5 mg/ml Sulfo-NHS-SS-biotin (Thermo Scientific, 30 min, 4 C), then rinsed in PBSCM, and unreacted biotinylation reagent was quenched in PBSCM containing 20 mM glycine (2 3 7 min, 4 C). Cells were lysed in lysis buffer (PBS containing 50 mM NaF, 5 mM sodium pyrophosphate, 1% NP-40, 0.5% sodium deoxycholate, 0.02% SDS, 1 mM okadaic acid, 1mM Na 3 VO 4 , and protease inhibitor cocktail [Roche] ). Protein concentration of each lysate was quantified using Bradford reagent (Bio-Rad), and equal amounts of protein were incubated overnight with NeutrAvidin coupledagarose beads (Thermo Scientific). Beads were washed three times with ice-cold lysis buffer, and biotinylated proteins were eluted with 23 SDS sample buffer. Cell-surface or total proteins were then subjected to SDS-PAGE and analyzed by western blot.
Immunocytochemistry
For surface AMPA receptor labeling, neurons were fixed for 5 min at room temperature in PBS containing 4% paraformaldehyde (PFA)/4% sucrose, rinsed with PBS, blocked with 10% goat serum in PBS for 30 min, and incubated with mouse anti-GluA1 (anti-N terminus) antibodies in PBS with 1% goat serum (2 hr). Coverslips were washed with PBS. In some experiments, neurons were permeabilized with 0.1% Triton X-100 followed by labeling with guinea pig anti-VGlut1 (2 hr). Coverslips were incubated with Alexa Fluor 568-conjugated goat anti-mouse and Alexa Fluor 647 goat anti-guinea pig secondary antibodies in PBS containing 1% goat serum for 45 min. After final washes with PBS, coverslips were mounted onto glass slides using Fluoromount-G (Southern Biotech). All steps were performed at room temperature. For all other immunocytochemistry experiments, neurons were fixed as above for 10 min, followed by PBS rinse and then permeabilized with 0.1% Triton X-100 in PBS for 10 min. Fixed neurons were then blocked as above and incubated with primary antibodies in PBS containing 1% goat serum overnight at 4 C. Neurons were rinsed, incubated with fluorescently labeled secondary antibodies, and mounted onto glass slides as above.
Images were obtained using a 510 laser scanning confocal microscope (Zeiss).
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